PTJ
ELVN icon

Paul Tudor Jones’s Enliven Therapeutics ELVN Stock Holding History

Paul Tudor Jones’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.04M Buy
+40,118
New +$1.7M ﹤0.01% 1931
2026
Q1 		– Sell
-29,673
Closed -$457K – 3789
2025
Q4 		$457K Buy
29,673
+13,370
+82% +$266K ﹤0.01% 2770
2025
Q3 		$334K Buy
+16,303
New +$329K ﹤0.01% 2917
2025
Q2 		– Sell
-13,363
Closed -$263K – 3376
2025
Q1 		$263K Buy
+13,363
New +$288K ﹤0.01% 2683
2024
Q3 		– Sell
-24,221
Closed -$566K – 2806
2024
Q2 		$566K Buy
+24,221
New +$510K ﹤0.01% 1750
2022
Q4 		– Sell
-6,126
Closed -$56K – 2503
2022
Q3 		$56K Sell
6,126
-6,847
-53% -$40.4K ﹤0.01% 2183
2022
Q2 		$63K Sell
12,973
-8
-0.1% -$39 ﹤0.01% 1949
2022
Q1 		$98K Hold
12,981
– – ﹤0.01% 1836
2021
Q4 		$117K Hold
12,981
– – ﹤0.01% 2221
2021
Q3 		$212K Buy
+12,981
New +$270K ﹤0.01% 2273

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Paul Tudor Jones's ELVN Position: Q2 2026 in Review

Paul Tudor Jones opened a new position in Enliven Therapeutics (ELVN) in Q2 2026: 40,118 shares worth $2.04M. The stake represents ﹤0.01% of the portfolio and ranks #1931 among its holdings. This is a return to the name: Paul Tudor Jones previously reported a position in ELVN as recently as Q4 2025.

Paul Tudor Jones first reported a position in ELVN in Q3 2021 and has held it in 10 quarters since. 209 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Paul Tudor Jones held 40,118 shares of Enliven Therapeutics worth $2.04M as of Q2 2026.
  • Enliven Therapeutics was a new Paul Tudor Jones position in Q2 2026.
  • Enliven Therapeutics made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #1931 holding.
  • Paul Tudor Jones first reported a position in Enliven Therapeutics in Q3 2021 and has held it in 10 quarters since.
  • 209 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.